We are live on ! Find out more
SPRB

Spruce Biosciences

32 hedge funds and large institutions have $65.6M invested in Spruce Biosciences in 2025 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,150% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 2

300% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 1

256% more funds holding

Funds holding: 932 (+23)

161% more capital invested

Capital invested by funds: $25.1M → $65.6M (+$40.5M)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

451.36% less ownership

Funds ownership: 521.79%70.43% (-451%)

Holders
32
Holders Change
+23
Holders Change %
+255.56%
% of All Funds
0.39%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.01%
New
25
Increased
4
Reduced
1
Closed
2
Calls
Puts
Net Calls
Net Calls Change

SPRB Hedge Fund Activity: Q4 2025 in Review

32 of the 8,252 institutional investors tracked by Wall St. Rank reported a position in Spruce Biosciences (SPRB) for Q4 2025, worth a combined $65.6M — up 161% from $25.1M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new SPRB positions and 2 closed out — a net gain of 23 holders — while 4 added to existing stakes and 1 trimmed.

The largest buyer was Ikarian Capital, adding an estimated $11.6M. The largest seller was Carlyle Group, cutting an estimated $306M.

  • 32 institutional investors held Spruce Biosciences (SPRB) as of Q4 2025, up from 9 in Q3 2025.
  • Funds reported $65.6M of Spruce Biosciences stock for Q4 2025, up 161% quarter-over-quarter.
  • 25 funds opened new Spruce Biosciences positions in Q4 2025 and 2 closed out, a net change of +23 holders.
  • The largest Spruce Biosciences buyer in Q4 2025 was Ikarian Capital, an estimated $11.6M added.
  • The largest Spruce Biosciences seller in Q4 2025 was Carlyle Group, an estimated $306M sold.

Based on aggregated 13F filings for Q4 2025.